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TRIP13 and APC15 drive mitotic exit by turnover of
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The mitotic checkpoint ensures accurate chromosome segregation through assembly of the
mitotic checkpoint complex (MCC), a soluble inhibitor of the anaphase-promoting complex/
cyclosome (APC/C) produced by unattached kinetochores. MCC is also assembled during
interphase by Mad1/Mad2 bound at nuclear pores, thereby preventing premature mitotic exit
prior to kinetochore maturation and checkpoint activation. Using degron tagging to rapidly
deplete the AAA+ ATPase TRIP13, we show that its catalytic activity is required to maintain a
pool of open-state Mad2 for MCC assembly, thereby supporting mitotic checkpoint activa-
tion, but is also required for timely mitotic exit through catalytic disassembly of MCC.
Strikingly, combining TRIP13 depletion with elimination of APC15-dependent Cdc20 ubiqui-
tination/degradation results in a complete inability to exit mitosis, even when MCC assembly
at unattached kinetochores is prevented. Thus, mitotic exit requires MCC produced either
in interphase or mitosis to be disassembled by TRIP13-catalyzed removal of Mad2 or
APC15-driven ubiquitination/degradation of its Cdc20 subunit.
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The mitotic checkpoint (or spindle-assembly checkpoint)delays the onset of anaphase until all chromosomes havesuccessfully attached to spindle microtubules, thereby
serving as the primary guard against chromosome missegrega-
tion. Anaphase onset is controlled by a multisubunit E3 ubiquitin
ligase, the anaphase-promoting complex/cyclosome (APC/C)1–4.
The APC/C, together with its co-activator Cdc20, targets cyclin B
and securin for proteasome-mediated destruction, thereby caus-
ing exit from mitosis and activation of separase [reviewed in
ref. 5]. The mitotic checkpoint functions through unattached
kinetochores, which generate a soluble mitotic checkpoint com-
plex (MCC) consisting of Mad2, Cdc20, BubR1, and Bub3. The
MCC binds the APC/CCdc20 complex as a substrate analog and
directly inhibits its activity6–8. While MCC is mainly produced in
mitosis by the mitotic checkpoint, low levels of MCC are also
produced in interphase cells, and this pool of MCC is thought to
be important for inhibiting early mitotic exit prior to kinetochore
maturation and mitotic checkpoint activation9–12.
The key component controlling MCC assembly is Mad2, an
essential checkpoint protein containing a HORMA domain13 that
can adopt two different conformations: “open” (O-Mad2) or
“closed” (C-Mad2). C-Mad2 binds partner proteins, including
Cdc20 and Mad1, through a distinctive “seat belt” interaction, in
which the Mad2 C-terminus embraces a short Mad2-interacting
motif (MIM) in the partner. In O-Mad2, the C-terminal seat
belt occupies the MIM binding site to prevent complex forma-
tion14–17. In vivo and in vitro evidence has shown that O-Mad2 is
recruited to Mad1:C-Mad2 complexes at unattached kine-
tochores, where it is converted to C-Mad2 and assembled with
Cdc20 to form the core of the mitotic checkpoint complex18–22.
After assembly of the Cdc20:C-Mad2 complex, recruitment of
BubR1 and Bub3 complete assembly of MCC, which binds to
APC/CCdc20 and inhibits its recognition of cyclin B and securin,
thereby delaying mitotic exit. Low-level MCC assembly in inter-
phase is thought to occur through a similar mechanism, catalyzed
by Mad1:C-Mad2 localized to nuclear pores11,23.
Once all kinetochores have become attached to microtubules, the
mitotic checkpoint is silenced and APC/CCdc20 is reactivated for
cyclin B and securin ubiquitination and their subsequent protea-
somal destruction, which in turn initiates anaphase onset. At each
kinetochore, stable microtubule attachment releases the Mad1:C-
Mad2 complex24–27 and PP1 phosphatase activity is elevated
to inactivate checkpoint kinases, including Mps1, thereby leading
to suppression of additional MCC production28–33. Existing
APC/CCdc20-bound MCC (APC/CCdc20-MCC) must then be dis-
assembled and/or degraded to reactivate APC/CCdc20 recognition of
cyclin B and securin. One proposed mechanism for APC/CCdc20
reactivation is ubiquitination of the Cdc20 subunit of MCC by the
inhibited APC/CCdc20 itself, which is enabled by a conformational
change within the APC/C allowing recruitment of an E2 enzyme
and ubiquitination of Cdc20 in MCC34–37. Loss of APC15, a 14 kD
APC/C subunit which is dispensable for APC/C assembly and
activity38–40, eliminates this reactivation pathway by preventing the
conformational change required for E2 recruitment and Cdc20
ubiquitination41,42. A second pathway potentially driving mitotic
exit has been proposed to involve the AAA+ ATPase TRIP13
acting with an adapter protein p31comet to extract Mad2 from the
assembled MCC. p31comet speciﬁcally binds C-Mad2 alone or in
complex with Cdc20 and other MCC subunits43–46. TRIP13 and
p31comet together can mediate disassembly of MCC complexes
in vitro47–49, acting by partially unfolding the N-terminus of C-
Mad2 to catalyze its conversion to O-Mad250-52. Whether and how
the two proposed pathways for MCC disassembly/degradation—
APC15-mediated ubiquitination/degradation and TRIP13-mediated
disassembly—synergize to mediate APC/CCdc20 activation and
mitotic checkpoint silencing is not known.
Despite its proposed role in MCC disassembly and checkpoint
silencing, deletion or complete loss of TRIP13 in C. elegans53 or
human cells54–56 causes defects in checkpoint activation, rather
than failure of checkpoint silencing. In the absence of TRIP13,
most soluble Mad2 is in the closed conformation, rendering it
unable to be recruited to unattached kinetochores and assembled
with Cdc20 into the MCC54. This ﬁnding, plus the observation
that puriﬁed O-Mad2 spontaneously converts to C-Mad2 in vitro
over the course of several hours17, suggests that TRIP13 is
required for mitotic checkpoint activation by maintaining a pool
of O-Mad2.
The proposed dual roles of TRIP13 in the mitotic checkpoint
mirror a similar duality in its observed roles in cancer. Recently, it
was shown that biallelic loss-of-function mutations in TRIP13
underlie mosaic variegated aneuploidy and Wilms tumor in
children, establishing TRIP13 as a bona ﬁde tumor suppressor55.
Conversely, several studies have highlighted that TRIP13 is
overexpressed in many cancer types, and that high-level TRIP13
expression correlates with poor patient outcomes57,58. The con-
tributions of TRIP13 to tumorigenesis and cancer progression
remain largely mysterious.
Here, we develop an inducible system to rapidly and com-
pletely deplete TRIP13 in cultured human cells by engineering
auxin-inducible degron (AID) tags into both endogenous
TRIP13 loci. Loss of TRIP13 during interphase is shown to
trigger checkpoint activation failure in the next mitosis due to a
loss of soluble O-Mad2. Conversely, cells that enter mitosis
soon after depletion of TRIP13, prior to full O-Mad2 to
C-Mad2 conversion, show a dramatic checkpoint-mediated
delay in mitotic exit, revealing TRIP13’s critical role in check-
point silencing. Further, we show that checkpoint silencing
involves TRIP13 acting synergistically with APC15-mediated
Cdc20 ubiquitination to disassemble or degrade, respectively,
soluble and APC/CCdc20-bound MCC. Strikingly, we ﬁnd that
mitotic exit requires MCC produced either in interphase or
mitosis to be disassembled by TRIP13-catalyzed removal of
Mad2 or APC15-driven ubiquitination/degradation of its
Cdc20 subunit.
Results
Long-term TRIP13 depletion compromises cell ﬁtness. To
determine the roles of TRIP13 in the mitotic checkpoint, we
sought to develop a means of acutely controlling TRIP13 levels
in live cells. We used CRISPR/Cas9 to sequentially introduce
sequences encoding green ﬂuorescent protein (GFP) and an
auxin-inducible degron (AID)59,60 into both TRIP13 alleles of
nearly diploid human DLD-1 cells (hereafter, TRIP13AID) also
stably expressing a ﬂuorescent histone H2B protein (H2B-
mRFP) and the TIR1-9Myc E3 ubiquitin ligase to permit
inducible ubiquitination of AID-tagged proteins (Fig. 1a). Upon
addition of indole-3-acetic acid (IAA), GFP-AID-TRIP13 was
rapidly degraded with a t1/2 of ~7 min (Fig. 1b, Supplementary
Fig. 1A), becoming undetectable (to <3% of its initial level)
within 30 min. No discernable difference in growth between
normal or TRIP13-depleted cells was seen after 3 days (Sup-
plementary Fig. 1B). We ﬁrst used time-lapse live-cell imaging
(using H2B-mRFP to monitor chromosome condensation and
decondensation) to examine the fate of cells in the ﬁrst mitosis
after TRIP13 depletion. Addition of nocodazole to inhibit
spindle microtubule assembly caused a chronic mitotic arrest in
TRIP13-containing cells (Fig. 1c, left panel), whereas most
cells entering mitosis ≥24 h after TRIP13 depletion exited
mitosis within 40 min (Fig. 1c; right panel). In unperturbed
mitoses (no nocodazole), the time from nuclear envelope
breakdown (NEBD) to chromosome alignment in metaphase
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was indistinguishable in the presence or absence of TRIP13
(~23 min, Fig. 1d; left panel), but in the absence of TRIP13 the
transition from metaphase-to-anaphase was accelerated (low-
ering it from ~20 to ~11 min; Fig. 1d, right panel). Normal
metaphase-to-anaphase timing could be rescued in TRIP13-
depleted cells by expression of wild-type TRIP13, but not with
TRIP13 bearing the Walker B motif E253Q mutation (TRI-
P13EQ), which allows for ATP binding and stabilizes the
TRIP13 hexamer, but eliminates ATP hydrolysis50,52 (Supple-
mentary Fig. 1C-F). These ﬁndings demonstrate that TRIP13 is
not strictly needed for entry into mitosis or for chromosome
congression, but is required for activation and/or maintenance
of the mitotic checkpoint.
Live-cell imaging of TRIP13AID cells revealed signiﬁcant errors
in chromosome segregation during anaphase of the ﬁrst mitosis
after TRIP13 depletion (Supplementary Fig. 1G) that drove
chromosomal aneuploidy in the daughter cells (as determined by
ﬂuorescence in situ hybridization (FISH) analyses—Fig. 1e).
Clonogenic assays indicated that prolonged (3 week) depletion of
TRIP13 resulted in signiﬁcantly smaller colony size compared to
TRIP13WT cells (Supplementary Fig. 1H). Collectively, this
evidence demonstrates that TRIP13 normally acts to prevent
aneuploidy and that loss of TRIP13 compromises long-term cell
ﬁtness.
TRIP13 maintains open Mad2 to support checkpoint activa-
tion. To examine Mad2 conformation in the absence of TRIP13,
we depleted TRIP13 in TRIP13AID cells by addition of IAA, and
examined Mad2 conformation in cell lysates by Mono-Q ion-
exchange chromatography (which separates the two Mad2
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conformers16,17,50,52). Mad2 was mostly in its open conformer
prior to TRIP13 depletion, in agreement with prior studies17
(Fig. 2a). Over time, however, Mad2 gradually converted to the
closed conformation, with a conversion half-time of ~1.4 h and
reaching an equilibrium at ~8% O-Mad2 (Fig. 2a, right panel).
This rate of conformational conversion is consistent with the
in vitro rate of spontaneous O-Mad2 to C-Mad2 conversion
(half-time; 1.5–2 h)61 and with the equilibrium percentage of O-
Mad2 seen in our earlier in vitro measurements50. These data
clearly indicate that a major role of TRIP13 is to counteract
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spontaneous conversion of O-Mad2 to C-Mad2, the latter of
which cannot be recruited to unattached kinetochores and
assembled into the MCC. Importantly, this conversion was not
related to cell-cycle progression: in cells arrested in G1 (by
addition of the Cdk4/6 inhibitor palbociclib62), >90% of Mad2
converted to the closed conformation within 12 h of TRIP13
depletion (Fig. 2b).
Cells chronically depleted of TRIP13 have been reported to show
changes in overall Mad2 and p31comet protein levels compared to
normal cells54,55. We observed similar changes upon TRIP13
depletion, including a ~2-fold reduction in Mad2 level and a
>5-fold increase in p31comet levels (Supplementary Fig. 3). When
we replaced endogenous Mad2 with a mutant (Mad2H191A) that
predominantly adopts the open conformation even in the absence
of TRIP1352,63, we did not observe increased p31comet levels upon
TRIP13 depletion (Supplementary Fig. 3F). Thus, p31comet is
stabilized by binding C-Mad2 and strongly accumulates in the
absence of TRIP1354.
To test whether the checkpoint activation defect upon longer-
term TRIP13 depletion was caused by insufﬁcient O-Mad2, we
stably integrated a gene encoding untagged, wild-type Mad2 into
a doxycycline-inducible FRT locus in the TRIP13AID cell line
(hereafter Mad2WT-Flp). We then depleted endogenous Mad2 by
siRNA and induced the Mad2WT-Flp gene (whose mRNA is
resistant to the siRNA) (Fig. 2c). In the presence of TRIP13, most
Mad2 produced from either the endogenous or Mad2WT-Flp
genes was in the form of O-Mad2 (Fig. 2d) and the cells traversed
mitosis with normal timing (Fig. 2e). In contrast to the nearly
complete conversion of endogenous Mad2 (Mad2WT-endo) to the
closed form after TRIP13 degradation (Fig. 2d), doxycycline-
mediated synthesis of new Mad2 resulted in a signiﬁcant pool of
soluble O-Mad2 even in the absence of TRIP13 (Fig. 2d), which in
turn supported a strong delay in the timing of mitotic exit in
these cells (Fig. 2e). Thus, newly synthesized Mad2 adopts the
O-Mad2 conformation and this new Mad2 is sufﬁcient to rescue
mitotic checkpoint activation in the absence of TRIP13, while the
subsequent delay in mitotic exit supports a role for TRIP13 in
MCC disassembly to permit anaphase onset.
TRIP13 has a critical role in mitotic checkpoint silencing. In
vitro, TRIP13 and its Mad2-binding adapter protein p31comet
have been shown to convert C-Mad2 to O-Mad250 and to release
Mad2 from Cdc20:C-Mad2 or the four-protein MCC47,48,64.
These ﬁndings, plus reports that RNAi-mediated reduction of
TRIP13 can slow mitotic exit in some cells49, have led to the idea
that TRIP13 and p31comet participate in checkpoint silencing. We
initially tested a role for TRIP13 in checkpoint silencing by
measuring the mitotic index (by scoring histone H3 serine 10
phosphorylation-positive cells) over time after inducing TRIP13
degradation. This revealed a sharp, transient increase in mitotic
cells between 1 and 3 h after TRIP13 degradation, consistent with
a TRIP13 role in mitotic checkpoint silencing and timely mitotic
exit (Fig. 2f). We then used time-lapse live-cell imaging to
determine that, despite unaffected NEBD-to-metaphase timing,
metaphase-to-anaphase timing was signiﬁcantly delayed (more
than tripling the typical 20 to 64 min) in cells entering mitosis
between 0 and 3 h after TRIP13 degradation (Fig. 2g).
Cells entering mitosis 3–6 h after TRIP13 degradation exited
mitosis with nearly wild-type timing, while cells entering
mitosis even later (6–16 h after TRIP13 degradation)
exited mitosis faster than wild-type cells (Fig. 2g), consistent with
failure of mitotic checkpoint activation and with the mitotic
timing we observed after 24-h TRIP13 depletion (Fig. 1d) and in
TRIP13−/− cells54.
To more clearly establish that the mitotic exit delay we
observed shortly after TRIP13 depletion was due to a defect in
mitotic checkpoint silencing, we next tested whether this delay
depended on Mad2 and actively signaling kinetochores. We used
siRNA to deplete Mad2 in TRIP13AID cells and then examined
mitotic timing shortly after TRIP13 depletion. Mad2-depleted
cells exited mitosis signiﬁcantly faster than untreated cells
regardless of whether or not TRIP13 was present (Supplementary
Fig. 2A). We next prevented MCC assembly at unattached
kinetochores by addition of reversine to inactivate the Mps1
kinase65, and found that this treatment also accelerated mitotic
exit both in the presence and absence of TRIP13 (Supplementary
Fig. 2B). Together, these data indicate that the delay in mitotic
exit that we observe shortly after TRIP13 depletion depends on
both Mad2 and actively signaling kinetochores, supporting a
direct role for TRIP13 in checkpoint silencing, most likely
through MCC disassembly after kinetochore-microtubule
attachment.
TRIP13 and APC15 act in parallel to inactivate MCC. Despite
the strong delay in mitotic exit in cells that entered mitosis within
3 h of TRIP13 degradation, these cells did eventually exit mitosis.
This observation indicated that MCC bound to APC/CCdc20 is
either able to spontaneously disassemble, or that it is dis-
assembled/degraded through an alternate pathway(s). Beyond
TRIP13-mediated disassembly of Mad2 from MCC48,49, another
proposed pathway involves ubiquitination of Cdc20 within MCC
bound to APC/CCdc20, resulting in Cdc20 degradation, MCC
disassembly, and reactivation of APC/CCdc20 for recognition of
cyclin B and securin34-37. For this second pathway, APC15, a 14
Fig. 2 TRIP13 regulates mitotic checkpoint activation and silencing through Mad2. a Upper: Schematic of experiment to test kinetics of Mad2
conformational conversion after TRIP13 depletion. Lower left: Mono-Q ion-exchange chromatography analysis of soluble Mad2 in TRIP13AID cells after IAA
treatment for the indicated times. Lower right: Kinetics of O-Mad2 to C-Mad2 conversion was calculated from triplicate measurements, ﬁt using a single-
exponential decay function (yellow line). t1/2= 1.4 ± 0.3 h, plateau= 8% O-Mad2 (gray dashed line). b Mad2 conformation in G1 after TRIP13 depletion.
TRIP13AID cells were arrested in G1 with Palbociclib and Mad2 conformation was measured by Mono-Q ion-exchange chromatography at 0 or 12 h after
addition of IAA to degrade TRIP13. c Upper: Schematic of the approach to replace endogenous Mad2 in TRIP13-depleted cells (used in d and e). Lower:
Immunoblot analysis of the replacement of endogenous Mad2 with Mad2WT-Flp induced by doxycycline. dMono-Q ion-exchange chromatography analysis
of Mad2 conformation after replacement of endogenous Mad2 with Mad2WT-Flp, in the presence (blue box) or absence (brown box) of TRIP13. High-level
expression of Mad2WT-Flp resulted in a signiﬁcant O-Mad2 population even after TRIP13 depletion. eMitotic timing (NEBD-to-anaphase) after replacement
of endogenous Mad2 with Mad2WT-Flp, measured by time-lapse live-cell imaging. (n= 100 for each condition). f Upper: Schematic of experiment to
measure population of mitotic TRIP13WT and TRIP13AID cells upon IAA treatment. Lower: Percentage of phospho-histone H3 (Ser10) positive cells was
measured using ﬂow cytometry at different time points after IAA treatment. Detailed FACS proﬁles in Supplementary Fig. 2D. g Upper: Schematic of
experiment to measure mitotic timing in TRIP13AID cells upon IAA treatment. Lower: NEBD-to-metaphase (left) and metaphase-to-anaphase (right) timing
of TRIP13AID cells at different time points after IAA addition. (From left to right panel, n= 50, 69, 56, 58, 176, 93, 70, and 110). Lines in e and g represent
the mean ± s.e.m.
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kDa APC/C subunit that is dispensable for overall APC/CCdc20
assembly and ubiquitination activity, has been implicated as a
required factor for ubiquitination of Cdc20 in MCC-bound
APC/CCdc20 through its promotion of a conformational change
in APC/C, which allows recruitment of an E2 enzyme and ubi-
quitination of Cdc20 in MCC41,42.
We tested whether mitotic exit in cells shortly after TRIP13
degradation depended on APC15-mediated Cdc20 ubiquitination
and degradation. To do this, we inactivated both APC15 alleles
using CRISPR-Cas9 in TRIP13 AID cells (Fig. 3a, hereafter,
TRIP13AID/APC15KO). We treated cells with nocodazole to
induce a mitotic checkpoint-mediated arrest, then released from
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nocodazole after rapid depletion of TRIP13 with auxin-induced
degradation, and tracked cell-cycle progression by live-cell
microscopy. While cells depleted of either APC15 or
TRIP13 showed delayed mitotic exit relative to wild-type cells,
these cells did eventually exit mitosis (Fig. 3b). In contrast, 100%
of cells depleted of both APC15 and TRIP13 were chronically
arrested in mitosis with none escaping over 20 h of ﬁlming
(Fig. 3b). We next tracked unperturbed mitosis in TRIP13AID/
APC15KO cells, and found that while these cells had normal
NEBD-to-metaphase timing and only a slight delay in mitotic exit
when TRIP13 was present (Fig. 3d, e), degradation of TRIP13 by
IAA treatment produced a durable metaphase arrest, with all cells
remaining arrested for the duration of ﬁlming (21–24 h) (Fig. 3e,
f). Finally, we treated mitotically arrested TRIP13AID/APC15KO
cells with reversine to eliminate kinetochore production of MCC.
We found that while cells retaining TRIP13 exited mitosis
quickly, 100% of cells lacking both APC15 and TRIP13 (after IAA
addition) remained mitotically arrested for at least 10 h (Fig. 3g).
Thus, in the absence of the known catalytic pathways for MCC
disassembly or degradation, cells are completely unable to
reactivate APC/CCdc20-MCC and exit mitosis, even in the absence
of any kinetochore signaling.
Mitotic exit relies on turnover of interphase-generated MCC.
Recently, multiple studies have indicated that in addition to being
assembled at unattached kinetochores in mitosis, MCC may be
generated at low levels outside of mitosis, likely by Mad1:Mad2
complexes localized at nuclear pores10,11. We tested if this pool of
MCC produced in interphase might be enough to delay mitotic
exit in the absence of the two catalytic MCC disassembly/degra-
dation pathways. We depleted TRIP13 and simultaneously added
reversine to eliminate kinetochore-dependent mitotic checkpoint
signaling in TRIP13AID/APC15KO cells, and examined mitotic
timing. Strikingly, 75% of cells lacking both APC15 and TRIP13
and which never activated the mitotic checkpoint remained
arrested in mitosis for the duration of 24 h of ﬁlming (Fig. 4a).
This prolonged mitotic arrest was dependent on both Mad2 and
BubR1 (Fig. 4b, Supplementary Fig. 4C), as would be expected
from a bona ﬁde MCC-mediated delay. These data not only
support the idea that a pool of MCC is synthesized in interphase
independently of kinetochores, but also demonstrate that this
interphase-produced pool of MCC is sufﬁcient to cause sustained
mitotic arrest in the absence of TRIP13 (and its catalytic MCC
disassembly activity) or APC15 (and its stimulation of ubiquiti-
nation/degradation of the Cdc20 subunit of MCC).
In interphase, Mad1:Mad2 are bound to the nucleoplasmic face
of the nuclear envelope through the TPR protein, and this pool of
Mad1:Mad2 has been implicated in production of MCC during
interphase9,11,23. To examine whether TPR (and its tethering of
Mad1:Mad2 to the nuclear pore11) is essential for MCC
generation by Mad1:Mad2 at the nuclear pore that is sufﬁcient
to trigger sustained mitotic arrest in the absence of TRIP13 and
APC15, we used RNAi to deplete TPR from TRIP13AID/
APC15KO cells (Supplementary Fig. 4,B) and monitored mitotic
timing (Fig. 4c). Like TPR-containing cells (Fig. 4a), TRIP13AID/
APC15KO cells entering mitosis after depletion of TPR (but
competent for kinetochore-dependent mitotic checkpoint activa-
tion) were almost completely (98%) arrested after IAA-induced
degradation of TRIP13 (Fig. 4c). However, when mitotic
checkpoint signaling was prevented (by addition of reversine),
reduced TPR levels sharply reduced the proportion of mitotically
arrested cells [from 75% (Fig. 4a) to 28% (Fig. 4c)], consistent
with TPR-dependent production of an APC/CCdc20 inhibitor.
Finally, we tested for the presence of MCC (either free or
bound to APC/CCdc20) in interphase TRIP13AID/APC15KO cells.
Cells were synchronized in either mid-G1 (by inhibiting CDK4/6
with Palbociclib) or in late G2 (by inhibiting CDK1 with RO-
3306) and the levels of BubR1-bound Cdc20 and Mad2
determined by immunoprecipitation and immunoblotting (Sup-
plementary Fig. 4D). In both G1 and late G2, low levels of APC/
C-associated BubR1 and Mad2 were detected in extracts from
cells containing TRIP13; much higher levels were found in
extracts of cells depleted of TRIP13 (by IAA-induced degrada-
tion) (Fig. 4d). Overall MCC levels (as measured by BubR1-
bound Mad2) also increased upon degradation of TRIP13 in G2-
arrested cells (Supplementary Fig. 4D). These data support a role
for TRIP13 in continual MCC disassembly throughout interphase
as well as mitosis.
To test whether MCC is bound to APC/C during interphase
when both TRIP13 and APC15 are missing, we monitored the
level of MCC components associated with the core APC/C
subunit APC3 in G1 or late G2-arrested TRIP13AID/APC15KO
cells. While a small proportion of BubR1 was recruited to APC/C
in the presence of TRIP13 in G1 cells (Fig. 4d), cells lacking
APC15 and TRIP13 accumulated up to ~8-fold higher levels of
APC/C-bound BubR1, Mad2, and Cdc20 (Fig. 4d). When
combined with our evidence for chronic mitotic arrest in the
absence of TRIP13, APC15, and mitotic checkpoint activation,
these data provide strong evidence that MCC produced in
interphase can quantitatively inhibit APC/CCdc20 and produce
chronic mitotic arrest when TRIP13 and APC15 are absent.
Discussion
Our use of rapid, inducible degradation of TRIP13 has demon-
strated that Mad2 conformation in vivo is highly dependent on
TRIP13 and its ATPase activity, with cellular O-Mad2 converted
to C-Mad2 with a half-time of 1.4 h in the absence of TRIP13
(Fig. 2a). Since this matches the kinetics of spontaneous con-
version of puriﬁed O-Mad2 to C-Mad2 in vitro61, our evidence
offers strong support that cellular O-Mad2 undergoes sponta-
neous conformational conversion in vivo that is independent of
other factors. We also show that after loss of TRIP13, insufﬁcient
soluble O-Mad2 at the time of mitotic entry results in failure of
mitotic checkpoint activation and that checkpoint activation can
be rescued by re-introduction of additional O-Mad2. Together,
these observations establish that a key function of TRIP13
throughout the cell cycle is to counteract the spontaneous con-
version of O-Mad2 to C-Mad2, thereby maintaining a pool of
soluble O-Mad2 which can be recruited to kinetochores in mitosis
to produce MCC (Fig. 5) and clarify the dual roles of TRIP13 in
mitotic checkpoint activation and silencing.
Our data also provide strong support for the idea that MCC is
assembled outside of mitosis by Mad1, Mad2, and TPR, the latter
of which tethers Mad1–Mad2 to the nuclear pore complex11,23.
Our evidence suggests that APC15 and TRIP13 mediate con-
tinuous turnover of interphase-produced MCC complexes, which
act both to restrain the activity of any APC/CCdc20 present in
interphase, and provide a baseline level of pre-made MCC to
delay mitotic exit prior to kinetochore maturation and mitotic
checkpoint activation. Thus, TRIP13 and APC15 activity serve as
a counter-balance to MCC assembly both in interphase and in
mitosis11. The delicate balance between MCC assembly and dis-
assembly/degradation pathways, and these pathways’ coordina-
tion through space and time, will be important to consider as the
contributions to cancer of both TRIP13 loss and overexpression
are further studied.
Mitotic checkpoint silencing is initiated when spindle micro-
tubules capture all kinetochores, thereby suppressing production
of new MCC through delocalization of kinetochore-bound Mad1:
C-Mad224–27 and reduced activity of kinetochore-bound
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checkpoint kinases28–33. A key question has been how
pre-existing free and APC/CCdc20-bound MCC are inactivated
by disassembly or degradation so as to reactivate APC/CCdc20.
We show here that two separate catalytic pathways
(TRIP13/p31comet-mediated MCC disassembly through
C-Mad2 to O-Mad2 conformational conversion47–50,52 and
APC15-dependent ubiquitination of Cdc20 in MCC) are essential
for inactivating MCC made either in interphase or in mitosis.
Indeed, we have found that once assembled, MCC complexes are
extraordinarily stable, with a negligible rate of spontaneous
inactivation, producing chronic mitotic arrest in cells lacking
both MCC disassembly and degradation pathways even in the
absence of actively signaling kinetochores (Fig. 5). Recently,
Brulotte et al.66 showed that in vitro low levels of TRIP13 were
unable to quickly reactivate APC/CCdc20 that had been pre-
incubated with MCC components, but were sufﬁcient to
disassemble-free MCC and prevent APC/CCdc20 inhibition. These
data clearly show that free MCC is the preferred substrate of
TRIP13, but does not eliminate the possibility of low-level activity
on APC/C-MCC complexes. Thus, while our data show that both
MCC disassembly pathways on their own are capable of med-
iating eventual mitotic exit, we postulate that in wild-type cells, a
division of labor exists where TRIP13/p31comet preferentially
disassembles free MCC, and APC15 catalyzes disassembly/
degradation of APC/C-bound MCC.
Cellular studies and recent high-resolution structures of MCC-
bound APC/CCdc20 have revealed that multiple degron sequences
in the BubR1 subunit of MCC occupy the substrate-binding sites
of Cdc20 to inhibit APC/C activity41,42. It is striking, then, that
the two MCC degradation/disassembly pathways do not target
BubR1 directly, instead targeting either Mad2 (in the case of
TRIP13/p31comet) or Cdc20 (in the case of APC15-mediated
ubiquitination). We have shown that while cells normally employ
both pathways in parallel, either pathway is sufﬁcient for eventual
mitotic exit. These data (1) reveal that both pathways can act on
APC/CCdc20-bound MCC (TRIP13 can also likely act on soluble
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MCC) and (2) show that disruption of MCC structure by removal
of either Mad2 or Cdc20 is sufﬁcient to relieve inhibition of APC/
CCdc20 from ubiquitination of cyclin B and securin. Earlier evi-
dence67 that nocodazole-treated cells depleted of TRIP13 activity
(by reduction of its p31comet adapter) remain mitotically arrested
after induced degradation of Mad2, but not BubR1, suggests that
TRIP13’s action on APC/CCdc20-MCC may remove BubR1 along
with Mad2 or destabilize the remaining MCC complex22. Indeed,
BubR1 release may lag behind removal of Mad2—potentially
explaining earlier observations of APC/CCdc20-bound “BBC”
complex (BubR1, Bub3, Cdc20)21,43,68, but it nonetheless even-
tually dissociates to enable APC/CCdc20 reactivation.
Methods
DNA constructs and site-directed mutagenesis. Full-length ORFs of TRIP13
were obtained from OriGene technologies (Rockville, MD). cDNAs of TRIP13 were
cloned into a pcDNA5/FRT/TO-based vector (Invitrogen) modiﬁed to contain an
amino-terminus LAP tag. pCDNA5/FRT/TO-Mad2WT was generated as described
in previous study52. TRIP13EQ variant (E253Q) was generated by QuickChangeII
site-directed mutagenesis kit (Agilent).
Cell culture and generation of stable cell lines. All the cell lines used in this
study were cultured in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM, Thermo
Fisher) supplemented with 10% tetracycline-free fetal bovine serum (Omega Sci-
entiﬁc) and 100 U/mL penicillin-streptomycin and maintained at 37 °C under 5%
CO2. TRIP13AID cells; TIR1 and H2BmRFP-expressing T-REx Flp-In DLD-1 cells60
were engineered by CRISPR/Cas9 and HR-mediated genome editing to integrate
green ﬂuorescent protein (GFP) and auxin-inducible degron (AID) in front of
TRIP13 locus (AID ORF was a kind gift from Masato Kanemaki; National Institute
of Genetics, Mishima, Japan).
Oligonucleotides containing sgRNA sequences targeting TRIP13 are inserted
into BbsI site in pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene 42230). pCR4-
Blunt TOPO (Invitrogen) containing EGFP-AID cDNA with two TRIP13
homology arms (~750 bp, respectively) at both ends was constructed using Gibson
assembly method (NEB). Two plasmids were co-transfected into DLD-1 TRex Flp-
In TIR1-9Myc via electroporation. Two days after transfection, GFP-positive single
cells were isolated using single-cell sorting (FACS-Vantage; Becton Dickinson).
Targeted cells were identiﬁed through genomic PCR and DNA sequencing, further
conﬁrmed by immunoblotting. To generate TRIP13AID/APC15KO cells, C11orf51
CRISPR/Cas9 KO Plasmid (Santa Cruz Biotechnology) was transfected into
TRIP13AID cells and targeted cells were identiﬁed by immunoblotting.
For generation stable cell line inducibly expressing LAP-TRIP13WT/EQ and
Mad2WT-Flp, pcDNA5/FRT/TO-LAP-TRIP13 or Mad2 were co-transfected with
pOG44 into TRIP13AID cells using X-tremeGENE 9 (Roche). Cells were selected
with 150 μg/mL hygromycin B (Thermo Fisher), and protein expression was
conﬁrmed by immunoblotting.
Doxycycline and the indole-3-acetic acid (IAA) were dissolved in water and
used at 1 μg/mL and 500 μM, respectively. For mitotic arrest, 0.33 μM nocodazole
(Sigma Aldrich) was used. For checkpoint inactivation, 2 μM reversine (Santa Cruz
Biotechnology) was used.
RNA interference. For depletion of endogenous proteins, TRIP13AID cells were
transfected with 50 nM of siRNA and Lipofectamine RNAiMAX (Thermo Fisher)
for 48 h (remaining) before analysis. siRNAs directed against the 3′ untranslated
region of Mad2, BubR1 or On-TARGETplus-non targeting siRNA; were purchased
from GE Dharmacon.
Time-lapse live-cell imaging. To determine mitotic timing, TRIP13AID cells were
seeded onto CELLSTAR μClear 96-well plate (Greiner bio-one) and images were
collected using a CQ1 confocal image cytometer (Yokogawa Electric Corporation)
with a ×40 objective. 5 × 2-μm z-sections in RFP (20% power, 150 ms, 30% gain)
were acquired in each ﬁeld at 2.5, 5, or 10-min intervals. Image acquisition and
data analysis were performed using ImageJ. To measure mitotic error rate, chro-
mosome lagging and chromosome misalignment were counted during anaphase
onset.
Cell growth, ﬂow cytometry, and clonogenic assays. For cell doubling time
measurements, cells were plated into six-well dishes in triplicate and counted at
three days intervals. For ﬂow cytometry analysis, ethanol-ﬁxed cells were stained
with 1 μg/mL Hoechst 33258 (Thermo Fisher) and Phospho Histone H3 (Ser10)
antibody conjugated with Alexa647 (Cell Signaling) and analyzed with a SH800 cell
sorter (Sony). For conﬁrmation of cell-cycle synchronization, ethanol-ﬁxed cells
were stained with 10 μg/mL propidium iodide and 50 μg/mL RNase A and analyzed
for DNA content by ﬂow cytometry on a BD LSR II instrument (BD Biosciences).
For clonogenic growth assays, 100 cells were plated into six-well dishes in triplicate
for 21 days. Methanol-ﬁxed colonies were stained with a 0.5% crystal violet, 25%
methanol solution, and quantiﬁed using ImageJ software.
DNA ﬂuorescent in situ hybridization (FISH). For FISH, TRIP13AID cells were
cultured in chambered slides (IBIDI) with or without IAA for 5 days and ﬁxed in
cold methanol:acetic acid (3:1) for 15 mins and dehydrated with 80% ethanol.
Centromere 4 enumeration painting probes (MetaSystems) was applied to
slides, sealed with a coverslip, co-denatured at 75 °C for 2 mins, and hybridized
overnight at 37 °C in a humidiﬁed chamber. Slides were subsequently washed with
0.4× SCC at 72 °C for 2 mins and rinsed in 2× SCC, 0.05% Tween-20 at room
temperature for 30 s. Slides were then rinsed in water, counterstained with DAPI,
and mounted in anti-fade solution. FISH images were acquired on a DeltaVision
Core system (GE Health Sciences) at ×60 magniﬁcation (5 × 1μm z-sections) and
maximum intensity projections were generated using softWoRx software.
Ion exchange and size-exclusion chromatography. For Mad2 conformation and
complexes formation analyses, we prepared fresh whole-cell lysate without freeze
and thaw to prevent conformation changes during preparation. For examination of
Mad2 conformation, ion-exchange chromatography was carried out as described in
Ye et al.52 Whole-cell lysates were injected onto a Mono-Q column (GE
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Healthcare) in buffer containing 25 mM Tris pH 7.4, 1 mMMgCl2, 1 mM EDTA, 1
mM DTT and 50mM NaCl, and then eluted with a gradient to 400 mM NaCl. For
examination of Mad2 complex formation, whole-cell lysates were injected onto a
Superdex 200 column (GE Healthcare). Fractions were collected and analyzed by
SDS-PAGE followed by immunoblot against Mad2, p31comet, and Mad1 antibodies.
Antibodies and immunoprecipitation. BubR11–322 was expressed in protein was
expressed in E. coli Rosetta2 (DE3) pLysS by induction with IPTG for 20 h at 20 °C,
then puriﬁed by Ni2+ afﬁnity (Ni-NTA; Qiagen). The protein was used to
immunize a rabbit for antisera. Anti-BubR1 antibody was puriﬁed by antigen
crosslinked HiTrap NHS-activated HP (GE Healthcare) column. Rabbit anti-
BubR1 (homemade, 1:10000), rabbit anti-TRIP13 (Bethyl, Cat# A303–605, 1:3000),
rabbit anti-Mad2 (Bethyl, Cat# A300-301A, 1:3000), mouse anti-p31comet
(Mad2L1BP) (Santa Cruz, Cat# SC-134381, 1:200), mouse anti-Cdc20 (Santa Cruz,
Cat# SC-136024, 1:200), mouse anti-APC3 (Cdc27) (Santa Cruz, Cat# SC-9972,
1:200), mouse anti-GAPDH (6C5) (Abcam, AB8245, 1:10000), and mouse anti-α-
tubulin (DM1α) (Abcam, AB7291, 1:10000) were used for immunoblotting. To
monitor MCC and APC/CMCC formation, rabbit anti-BUBR1 or mouse anti-APC3
were conjugated to M-270 epoxy Dynal bead using Dynabead antibody coupling
kit (Thermo Fisher). For immunoprecipitation, conjugated antibodies were mixed
with precleared whole-cell lysates that have 1 mg total protein, and rotated for 90
min at 4 °C. After three times washing with lysis buffer (20 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 0.2% NP-40), the beads were treated with 30 μL 2×
SDS sample buffer and boiled for 5 min. Uncropped western blots are shown in
Supplementary Figure 5.
Protein puriﬁcation. For in vitro characterization of wild-type Mad2 or
Mad2H191A (both of which contained the R133A mutation to reduce homo-
dimerization), protein was expressed in E. coli Rosetta2 (DE3) pLysS by induction
with IPTG for 20 h at 20 °C, then puriﬁed by Ni2+ afﬁnity (Ni-NTA; Qiagen) and
ion-exchange (HiTrap Q HP; GE Life Sciences) chromatography. His6-SUMO tags
were cleaved by incubation with S. cerevisiae Ulp1 at 4 °C overnight, and cleaved
protein was passed over a Ni2+ afﬁnity column a second time to remove uncleaved
protein, His6-SUMO tags, and Ulp1. Protein was puriﬁed by size-exclusion chro-
matography (Superdex 200, GE Life Sciences), concentrated by ultraﬁltration, and
stored at −80 °C for biochemical assays.
Quantiﬁcation and statistical analysis. For quantiﬁcation of TRIP13 and Mad2,
triplicate samples were analyzed on independent Western blots, band intensity
measured by ImageJ, and points plotted as mean ± standard deviation. Degrada-
tion/conformational conversion half-times were calculated in Prism v. 7 using a
single-exponential decay model (plateau value set to 0% for TRIP13 degradation,
but allowed to ﬂoat for MAD2 conversion). For analysis of cell-cycle timing, at least
50 cells were tracked by live-cell imaging at 1–5 min intervals (depending on
experiment), and are plotted as mean ± s.e.m. (standard error of the mean). For all
panels showing P-values, these were calculated in Prism v. 7 using an unpaired
two-tailed t-test (**P < 0.01, ***P < 0.001, NS= not signiﬁcant).
Data availability
The data that support the ﬁndings of this study are available from the authors on
reasonable request, see author contributions for speciﬁc data sets.
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